While many people like the idea of a tablet, confidence still depends on whether patients believe pills can deliver results comparable to injections
Factors such as adherence to the medication, individual metabolism, and lifestyle choices all influence the timeline for visible results
Last December, the GLP-1 drug Wegovy was conditionally approved by Health Canada as the countrys first-ever pharmaceutical treatment for MASH
Once in circulation, it activates two receptors that the gut normally talks to after a meal: GIP and GLP-1
Maybe they would be more effective. The GLP-1 receptor agonists include semaglutide, which is marketed as Ozempic for diabetes and Wegovy for obesity, and tirzepatide, marketed as Zepbound for obesity and Mounjaro for diabetes
[DOI] [PMC free article] [PubMed] [Google Scholar] 266.Song HJ, Han HR, Lee JE, et al